期刊文献+

胃癌组织中骨桥蛋白与尿激酶型纤溶酶原激活物的表达 被引量:5

Expression of osteopontin and uPA in gastric carcinoma tissue
下载PDF
导出
摘要 目的:探讨胃癌组织中骨桥蛋白(OPN)与尿激酶型纤溶酶原激活剂(uPA)的表达及二者的表达与胃癌侵袭、转移间的关系。方法:应用免疫组织化学方法检测67例进展期胃癌组织、20例癌旁正常组织中OPN与uPA蛋白的表达。结果:67例胃癌组织中OPN与uPA蛋白的阳性表达率分别为70.1%(47/67)、64.2%(43/67)。OPN与uPA的表达与肿瘤组织类型、临床病理分期、浸润深度、淋巴结转移程度及有无远处转移有关(P<0.05),与患者年龄、性别及肿瘤的分化程度无关(P>0.05)。胃癌组织中OPN与uPA蛋白的表达呈正相关(rs=0.669,P<0.05)。结论:OPN、uPA蛋白与胃癌侵袭转移密切相关,能够作为反映肿瘤的生物学特性及评估预后的重要参考指标。 Aim: To investigate the expressions of osteopontin(OPN) and urokinase-type plasminogen activator(uPA) and their relation to the invasiveness and metastasis of gastric carcinoma. Methods:The expression of OPN and uPA in 67 cases of gastric carcinoma tissue and 20 cases of adjacent normal tissue was detected using immunohistochemistry method. Results: In gastric cancer tissue, the positive expression rates of OPN and uPA were 70. 1% (47/67) and 64.2% (43/ 67) ,respectively. The expression of OPN and uPA was related to histological type, pathological stage, invasion depth ,lymphatic and distant metastasis( P 〈 0.05 ) , but not related to age, sex or differentiation degree( P 〉 0.05 ). The expression of OPN was positively correlated with that of uPA in gastric carcinoma tissue ( rs = 0. 669,P 〈 0.05). Conclusion : Both OPN and uPA are significantly related to the invasiveness and metastasis of gastric carcinoma. The expression of them can reflect the biological characteristics of gastric carcinoma and could be used as important indicator in prognosis of gastric carcinoma.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2007年第5期906-908,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 骨桥蛋白 尿激酶型纤溶酶原激活物 胃肿瘤 侵袭转移 osteopontin uPA gastric neoplasm invasiveness and matastasis
  • 相关文献

参考文献9

  • 1周明锴,赵治国,常卫华,秦胜利,崔新征.人胃癌组织中C-Met与骨桥蛋白的表达[J].郑州大学学报(医学版),2006,41(2):326-328. 被引量:3
  • 2Rudland PS,Platt-Higgins A,El-Tanani M,et al.Prognostic significance of the matastasis-associated protein osteopontin in human breast cancer[J].Cancer Res,2002,62(12):3 417.
  • 3Zhu M,Gokhale VM,Szabo L,et al.Identification of a novel inhibitor of urokinase-type plasminogen activator[J].Mol Cancer Ther,2007,6(4):1 348.
  • 4孙现军,姜希宏,侯文红,马恒.骨桥蛋白与MMP-9在胃癌中的表达及其与临床病理特征的关系[J].肿瘤防治杂志,2003,10(4):370-372. 被引量:15
  • 5Denhardt DT,Mistretta D,Chambers AF,et al.Transcriptional regulation of osteopontin and the metastatic phenotype:evidence for a Ras-activated enhancer in the human OPN promoter[J].Clin Exp Metastasis,2003,20(1):77.
  • 6Kim TD,Song KS,Li G,et al.Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer[J].BMC Cancer,2006,6:211.
  • 7Bauer TW,Fan F,Liu W,et al.Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor[J].Ann Surg,2005,241(5):748.
  • 8Das R,Mahabeleshwar GH,Kundu DC.Osteopontin stimulates cell motilioty and nuclear factors kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylionsitol 3-kinase/Akt signaling pathways in breast cancer cells[J].J Biol Chem,2003,278(31):28 593.
  • 9周洁,李华仁,董红林,张锦波,权莉.胃癌及肠上皮化生组织中P53、C-myc蛋白表达[J].第一军医大学分校学报,2004,27(1):5-6. 被引量:1

二级参考文献22

  • 1[1]Crawford HC,Matrisian LM,Liaw L. Distinct role of osteopontin in host defense activity and tumor survival during sqamous cell carcinoma progression in vivo[J].Cancer Res,1998,58(22):5206-5215.
  • 2[2]Takahashi F,Takahashi K,Maeda K,et al. Osteopontin is induced by nitric oxide in RAW264.7 cells[J].IUBMB Life,2000,49(2):217-221.
  • 3[3]Denhardt DT,Giachelli CM,Rittling SR. Role of Osteopontin in celluar signaling ang toxicant injury[J].Ann Rev Pharmacol Toxicol,2001,41(3):723-749.
  • 4[4]Oidberg A,Franzen A,Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding seqence[J].Proc Natl Acad Sci USA,1986,83(5):8819-8823.
  • 5[5]Tuck AB,O'Malley FP,Singhal H,et al. Osteopontin expression in a group of lymph node negative breast cancer patients[J].Int J Cancer (Pred Oncol),1998,79(4):502-508.
  • 6[6]Agrawal D,Chen T,Irby R,et al. Osteopontin identified as lead marker of colon cancer progression,using pooled sample expression profiling[J].J Natl Cancer Inst,2002,94(7):513-521.
  • 7[7]Teruyoshi UE,Yokozaki H,Kitadai Y,et al. Co-Expression of osteopontin and CD44V9 in gastric cancer[J].Int J Cancer,1998,79(1):127-132.
  • 8[8]Craig AM,Bowden GT,Chambers AF,et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts[J].Int J Cancer,1990,46(1):133-137.
  • 9[9]Behrend EI,Craig AM,Wilson SM,et al. Reduced malignancy of ras-transformed NIH3T3 cells expressing antisense osteopontin RNA[J].Cancer Res,1994,54(3):832-837.
  • 10[10]Scorilas A,Karameris A,Arnogiannaki N,et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer:a potential favourable indicator in node-negative patients[J].Br J Cancer,2001,84(11):1488-1496.

共引文献15

同被引文献51

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部